17 Crore: Most costly Lifeline injection for SMA Afflicted Children

Pediatricians attribute this to extensive research and development, coupled with the drug's potential to save lives in a niche market.

Medicine Drugs Injection Vaccine Syringe
Picture: Pixabay

Last Updated on January 20, 2024 by The Health Master

Lifeline injection

Lifeline injection: In the heart-wrenching landscape of rare genetic diseases, spinal muscular atrophy (SMA) stands as a formidable adversary.

The recent spotlight on a 15-month-old in Karnataka, India, grappling with SMA, has thrust the exorbitant cost of the Zolgensma injection into the limelight.

This article delves into the intricacies of Zolgensma, its efficacy, prohibitive costs, and the broader context of SMA treatment.

Understanding SMA: A Nerve-Wracking Challenge

1. The Enigma of SMA

SMA, a rare genetic disease affecting motor neurons, poses a daunting challenge.

Mutations in the SMN gene lead to muscle weakness, paralysis, and, in severe cases, death.

2. Zolgensma’s Mechanism

Unpacking the science behind Zolgensma, developed by Novartis, reveals a therapy designed to deliver a functional SMN gene copy into motor neuron cells.

This, in turn, enhances muscle movement, offering a glimmer of hope to SMA-afflicted children.

3. The Survival Struggle

Experts weigh in on the recent improvements in SMA survival due to supportive care measures like physiotherapy and respiratory support.

However, the article emphasizes the need for more definitive solutions.

The Financial Conundrum: Why the 17 Crore Price Tag?

4. Deciphering the Cost Quandary

The staggering cost of Zolgensma, approximately Rs 17 crore, raises eyebrows.

Pediatricians attribute this to extensive research and development, coupled with the drug’s potential to save lives in a niche market.

5. Market Dynamics

Delving into the limited market size and the potential long-term benefits, the article explores the argument that Zolgensma’s expense might eventually offset other healthcare costs associated with SMA.

Eligibility and Administration: Narrowing the Scope

6. Target Demographic

Zolgensma is tailor-made for children under two diagnosed with SMA through genetic testing.

The article dissects the eligibility criteria, narrowing down the focus on a specific age group.

7. Administration Process

Detailing the administration process, the article explains the one-time infusion over an hour, shedding light on the drug’s intended impact on muscle movement and developmental milestones.

8. Global Access Initiatives

Highlighting global access programs, the piece underlines Novartis’s efforts to provide free therapy to children in 36 countries, where Zolgensma awaits official approval.

Efficacy and Limitations: Navigating the Nuances

9. USFDA Approval and Beyond

The article explores the USFDA’s approval of Zolgensma in 2019, emphasizing that while the therapy isn’t a definitive solution, it significantly hampers SMA progression.

10. The Indian Scenario

With Zolgensma yet to gain approval or manufacturing status in India, the article examines the options available to SMA-diagnosed patients within the country.

11. Side Effects Scrutinized

Considering the medical perspective, the common side effects of Zolgensma – elevated liver enzymes and vomiting – are scrutinized, underscoring the importance of careful monitoring.

Alternatives and Future Prospects: A Glimpse Beyond Zolgensma

12. Alternatives in SMA Treatment

Apart from Zolgensma, the article introduces alternatives like Spinraza and Evrysdi, emphasizing the varying costs, administration methods, and their role in SMA management.

13. Cost Comparison

A comparative analysis between Zolgensma and other treatments unravels cost efficiencies, offering insights into the economic considerations associated with SMA therapy.

14. Evrysdi: A Lifelong Commitment

Exploring Evrysdi, the first oral drug for SMA, the article details its daily oral administration, highlighting its DCGI approval and current status in India.

15. The Financial Strain

Child neurologist Sheffali Gulati sheds light on the financial strain associated with alternative treatments, emphasizing the economic challenges faced by families grappling with SMA.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
YouTube Icon